Canaccord analyst Elyse Shapiro downgraded Mayne Pharma to Hold from Buy with a price target of A$3.80, down from A$7.40. The analyst sees a lot for new management to work through after the company divested its retail generics portfolio.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MAYNF: